Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia
This is a phase I/II, open-label, multicenter study to assess the efficacy and safety of IM19 CAR-T cells in R/R B-cell Acute Lymphoblastic Leukemia
Leukemia
BIOLOGICAL: IM19 CAR-T cells
Incidence of Treatment Related adverse events (AEs), Up to 28 days after CAR-T cell infusion|Persistence of CAR-T cells (cell counts and cell percentage in peripheral blood and bone marrow), The persistence over time of CAR T cells in the peripheral blood as determined by flow cytometry and qPCR., Up to 24 weeks after CAR-T cell infusion
Objective response rate (ORR), At 28 days, 3 months and 6 months after CAR-T cell infusion|Anti-therapeutic IM19 CAR-T cells antibody, Up to 24 weeks after CAR-T cell infusion
This is a phase I/II, open-label, multicenter study to assess the efficacy and safety of IM19 CAR-T cells in R/R B-cell Acute Lymphoblastic Leukemia